Cresco Labs (CRLBF) Cash from Financing Activities (2019 - 2025)
Cresco Labs (CRLBF) posted Cash from Financing Activities of -$1.8 million for Q4 2025, up 97.48% on a QoQ basis from -$71.1 million in Q3 2025, and up 95.73% year-over-year from -$916037.2 in Q4 2024.
Cresco Labs (CRLBF) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Cresco Labs' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$1.8 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 95.73% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$117.4 million (down 207.07% YoY) and the FY2025 annual result came in at -$82.1 million, down 14.84% from the prior year.
- Cash from Financing Activities was -$1.8 million for Q4 2025 at Cresco Labs, up from -$71.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $132.2 million in Q1 2021 and bottomed at -$71.1 million in Q3 2025.
- A 5-year average of $371486.6 and a median of -$3.1 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 860.8% — and 2025, when it plunged 2785.39%.
- Cresco Labs' Cash from Financing Activities stood at -$2.4 million in 2021, then advanced by 14.48% to -$2.0 million in 2022, then plunged by 86.21% to -$3.8 million in 2023, then tumbled by 1011.42% to -$42.0 million in 2024, then surged by 95.73% to -$1.8 million in 2025.
- Business Quant data shows CRLBF's Cash from Financing Activities at -$1.8 million in Q4 2025, -$71.1 million in Q3 2025, and -$42.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.79 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | -71.10 Mn |
| Sep 30, 2025 | -71.10 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Dec 31, 2022 | -2.03 Mn |
| Dec 31, 2022 | -2.03 Mn |
| Sep 30, 2022 | -9.11 Mn |
| Sep 30, 2022 | -9.11 Mn |
| Jun 30, 2022 | -69.14 Mn |
| Jun 30, 2022 | -69.14 Mn |
| Mar 31, 2022 | -6.37 Mn |
| Mar 31, 2022 | -6.37 Mn |